Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.


Date Title Topic
02 Feb 2018 Gut Bacteria Can Affect Patient Responses to Anti-PD1 Immunotherapy Translational research - Cancer Immunology and Immunotherapy
01 Feb 2018 Fusions in Solid Tumours Pathology/Molecular biology - Personalised medicine
31 Jan 2018 ESMO Supports World Cancer Day 2018
31 Jan 2018 FDA Approves Lutetium Lu 177 Dotatate for Treatment of GEP NETs Endocrine and neuroendocrine tumours
30 Jan 2018 Withdrawal of the EU Marketing Authorisation Application for Binimetinib Melanoma and other skin tumours - Anticancer agents & Biologic therapy
29 Jan 2018 Withdrawal of the Application for a Change to the EU Marketing Authorisation for Nivolumab Gastrointestinal cancers - Cancer Immunology and Immunotherapy
26 Jan 2018 NICE Issues Technology Appraisal Guidance on Lenvatinib with Everolimus for Previously Treated Advanced RCC Genitourinary cancers - Anticancer agents & Biologic therapy
25 Jan 2018 NICE Publishes a Technology Appraisal Guidance for Ceritinib for Untreated ALK-positive NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
24 Jan 2018 EMA Recommends Refusal of the Marketing Authorisation for Plitidepsin Haematologic malignancies - Anticancer agents & Biologic therapy
23 Jan 2018 NICE Develops a Medtech Innovation Briefing on the MammaTyper In Vitro Diagnostic Test Breast cancer - Pathology/Molecular biology - Personalised medicine
19 Jan 2018 NICE Issues Medtech Innovation Briefing on Plasma EGFR Mutation Tests for Adults with Locally Advanced or Metastatic NSCLC Lung and other thoracic tumours - Personalised medicine
18 Jan 2018 RET Driven Cancers Anticancer agents & Biologic therapy
17 Jan 2018 FDA Broadens Afatinib Indication to Previously Untreated, Metastatic NSCLC with Other Non-resistant EGFR Mutations Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
15 Jan 2018 FDA Approves Olaparib for Germline BRCA-Mutated Metastatic Breast Cancer Breast cancer - Personalised medicine - Anticancer agents & Biologic therapy
10 Jan 2018 FDA Approves Denosumab for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma Haematologic malignancies - Palliative and supportive care